Suchergebnisse - "Pogue, Jason M"

PubPharm (30)

1

A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020) : Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints

enthalten in: Microbiology spectrum | 2022

von Gupta, V. | Yu, K. | Pogue, J. | +2

2

Antibiotic Overuse After Hospital Discharge : A Multi-hospital Cohort Study

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2021

von Vaughn, V. | Gandhi, T. | Chopra, V. | +10

3

Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2021

von Somers, E. | Eschenauer, G. | Troost, J. | +19

UpdateOf: medRxiv. 2020 Jun 03;:. - PMID 32577684

4

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP) : a randomised, double-blind, phase 3, non-inferiority trial

enthalten in: The Lancet. Infectious diseases | 2021

von Wunderink, R. | Matsunaga, Y. | Ariyasu, M. | +10

CommentIn: Lancet Infect Dis. 2021 Feb;21(2):153-155. - PMID 33058794

5

Agents of Last Resort : An Update on Polymyxin Resistance

enthalten in: Infectious disease clinics of North America | 2020

von Yang, Q. | Pogue, J. | Li, Z. | +3

6

ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients : Clinician-Centered Design and Development Study

enthalten in: JMIR mHealth and uHealth | 2020

von Hua, X. | Li, C. | Pogue, J. | +8

ErratumIn: JMIR Mhealth Uhealth. 2020 Dec 18;8(12):e26593. - PMID 33338026

7

Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2020

von Pogue, J. | Kaye, K. | Veve, M. | +9

CommentIn: Clin Infect Dis. 2020 Oct 23;71(7):1801-1802. - PMID 31904808

8

International Consensus Guidelines for the Optimal Use of the Polymyxins : Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

enthalten in: Pharmacotherapy | 2019

von Tsuji, B. | Pogue, J. | Zavascki, A. | +15

CommentIn: Pharmacotherapy. 2019 Jan;39(1):7-9. - PMID 30623457

9

The hypothetical impact of Accelerate Pheno™ system on time to effective therapy and time to definitive therapy in an institution with an established antimicrobial stewardship programme currently utilizing rapid genotypic organism/resistance marker identification

enthalten in: The Journal of antimicrobial chemotherapy | 2019

von Henig, O. | Cooper, C. | Kaye, K. | +9

10

Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model

enthalten in: The Journal of antimicrobial chemotherapy | 2018

von Barber, K. | Pogue, J. | Warnock, H. | +2